Norepinephrine tartrate is a potent agonist of adrenergic receptor (AR). Norepinephrine activates α1, α2, β1 receptors.

Indusatumab vedotin (MLN-0264) is an antibody-drug conjugate (ADC) composed of an anti-human GUCY2C (Guanylate cyclase 2C) monoclonal antibody and a anti-mitotic cytotoxic agent, monomethyl auristatin E (MMAE).

Telisotuzumab vedotin (Teliso-V, ABBV-399) is an antibody-drug conjugate (ADC) composed of the anti–c-Met humanized monoclonal antibody coupled to the cytotoxic monomethyl auristatin E (MMAE) through a mc-val-cit-PABC type linker. Telisotuzumab vedotin can be used for research on advanced solid tumours.

Trastuzumab duocarmazine ((vic)-Trastuzumab duocarmazine) is a HER2-targeting ADC that is recognized and cleaved by histone B in tumor cells and selectively targets tumor cells. Trastuzumab duocarmazine has anti-tumor activity and can be used in cancer research related to uterine and ovarian sarcomas[1].

Trastuzumab MMAE is an antibody-drug conjugate (ADC) composed of an anti-HER2 antibody, conjugated to Monomethyl Auristatin E (MMAE), via a Mc linker. Trastuzumab MMAE has the potential for use in research of solid tumors mainly in HER2-positive breast cancer.

Depatuxizumab Mafodotin (Depatux-M, ABT-414) is an antibody-drug conjugate consisting of an EGFR IGg1 monoclonal antibody conjugated to the tubulin inhibitor monomethyl auristatin F via a stable maleimidocaproyl link. Depatuxizumab Mafodotin is used in the treatment of recurrent EGFR-amplified Glioblastoma (GBM).

Enapotamab vedotin (EnaV, HuMAX-AXL-ADC) is an AXL-specific human IgG1 antibody conjugated to the microtubule disrupting agent monomethyl auristatin E (MMAE) through a protease cleavable valine-citrulline (vc) linker.

Zilovertamab vedotin (VLS-101, MK-2140) is an antibody-drug conjugate (ADC) composed of a humanised monoclonal antibody targeting ROR1 and the anti-mitotic cytotoxic agent monomethyl auristatin E (MMAE). It has potential for the treatment of lymphoid malignancies.

Patritumab deruxtecan (HER3-DXd) is an antibody-drug conjugate (ADC) consisting of a fully human anti-HER3 IgG1 monoclonal antibody Patritumab (HY-P99275) attached to a topoisomerase I inhibitor payload via a tetrapeptide-based cleavable linker. Patritumab deruxtecan shows anticancer activity[1].

Cantuzumab mertansine (SB-408075; huC242-DM1), an ADC, is an immunoconjugate of the potent maytansine derivative (DM1; HY-19792) and the humanized monoclonal antibody (huC242) directed to CanAg. Cantuzumab mertansine has cytotoxic toward colon cancer cells and has broad antitumor efficacy against a range of CanAg-positive human tumor xenografts[1][2].

Clivatuzumab-MMAE is an antibody-drug conjugate (ADC) composed of a humanized anti-mucin (MUC1) monoclonal antibody and a anti-mitotic cytotoxic agent monomethyl auristatin (MMAE).

Farletuzumab-MMAE is an antibody-drug conjugate (ADC) composed of humanized anti-human folate receptor-alpha (FRα) and the cytotoxic agent monomethyl auristatin (MMAE) via a MC-Vc linker. It has a potent antitumor activity.

L-ascorbic acid 2-phosphate (2-Phospho-L-ascorbic acid) magnesium hydrate is a long-acting vitamin C derivative that can stimulate collagen formation and expression. L-ascorbic acid 2-phosphate magnesium hydrate can be used as a culture medium supplement for the osteogenic differentiation of human adipose stem cells (hASCs). L-ascorbic acid 2-phosphate magnesium hydrate increases alkaline phosphatase (ALP) activity and expression of runx2A in hASCs during the osteogenic differentiation[1][2][3].

1-PHENYL-2-THIOUREA(N-Phenylthiourea, PTU, Phenylthiocarbamide) is an inhibitor of tyrosinase (Tyr). 1-PHENYL-2-THIOUREA blocks pigmentation and improves optical transparency in zebrafish (Danio rerio) embryo.

Kojic acid dipalmitate (Kojic dipalmitate) is a derivative of Kojic acid (HY-W050154), a fungal metabolite that can be produced by species of Aspergillus, Acetobacter and Penicillium. Kojic acid dipalmitate is a slow and reversible competitive inhibitor of tyrosinase. Kojic acid dipalmitate can be used for skin‐lightening agent research[1].

HA Peptide (HA tag) is a nine amino acids peptide derived from the human influenza hemagglutinin (HA). It is extensively used to isolate, purify, detect, and track the protein of interest in cell biology and biochemistry.

LIS10W is a sugar-alcohol-derived ionizable lipid with L-sorbitol as the precursor. CD40L-LIS10W in the CATCH (CD40L-LIS10W+CD40-BDMCs) treatment simultaneously induces ICD and CD40L expressions in tumoural tissues, which enables to activate both endogenous DCs and adoptively transferred CD40-BMDCs.

Penicillin-Streptomycin is used to prevent microbial contamination of cell culture during long-term in vitro cell culture maintenance.

Belantamab mafodotin (GSK2857916) is a humanized, afucosylated, anti-B-cell maturation antigen (BCMA) monoclonal antibody-drug conjugate (ADC) conjugated to MMAF (HY-15579) via a maleimidocaproyl linker (McMMAF, HY-15578). Belantamab mafodotin shows anti-myeloma activity[1][2].

Codrituzumab-MMAE, is an antibody-drug conjugate composed of a anti-GPC3 monoclonal antibody and a cytotoxic tubulin polymerase inhibitor conjugated through MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) type linker.

Pifithrin-β (PFT β hydrobromide; Cyclic Pifithrin-α hydrobromide) is a potent inhibitor of p53 with an IC50 of 23 μM and is regarded as a lead compound for cancer and neurodegenerative disease therapy.